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ABSTRACT
We investigated mechanisms resulting in low bone mineral density (BMD) and susceptibility to fracture by comparing noncoding
RNAs (ncRNAs) in biopsies of non–weight-bearing (NWB) iliac (n = 84) and weight bearing (WB) femoral (n = 18) postmenopausal
bone across BMDs varying from normal (T-score > −1.0) to osteoporotic (T-score ≤ −2.5). Global bone ncRNA concentrations were
determined by PCR andmicrochip analyses. Association with BMD or fracture, adjusted by age and body mass index, were calculated
using linear and logistic regression and least absolute shrinkage and selection operator (Lasso) analysis. At 10% false discovery rate
(FDR), 75 iliac bone ncRNAs and 94 femoral bone ncRNAs were associated with total hip BMD. Eight of the ncRNAs were common for
the two sites, but ﬁve of them (miR-484, miR-328-3p, miR-27a-5p, miR-28-3p, andmiR-409-3p) correlated positively to BMD in femoral
bone, but negatively in iliac bone. Of predicted pathways recognized in bone metabolism, ECM-receptor interaction and proteogly-
cans in cancer emerged at both sites, whereas fatty acid metabolism and focal adhesion were only identiﬁed in iliac bone. Lasso anal-
ysis and cross-validations identiﬁed sets of nine bone ncRNAs correlating strongly with adjusted total hip BMD in both femoral and
iliac bone. Twenty-eight iliac ncRNAs were associated with risk of fracture (FDR < 0.1). The small nucleolar RNAs, RNU44 and RNU48,
have a function in stabilization of ribosomal RNAs (rRNAs), and their association with fracture and BMD suggest that aberrant proces-
sing of rRNAs may be involved in development of osteoporosis. Cis-eQTL (expressed quantitative trait loci) analysis of the iliac bone
biopsies identiﬁed two loci associated with microRNAs (miRNAs), one previously identiﬁed in a heel-BMD genomewide association
study (GWAS). In this comprehensive investigation of the skeletal genetic background in postmenopausal women, we identiﬁed func-
tional bone ncRNAs associated to fracture and BMD, representing distinct subsets in WB and NWB skeletal sites. © 2020 The Authors.
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Introduction
Postmenopausal osteoporosis is the most common disease inwomen above 50 years of age, leading to fragile bone and
fractures even after mild skeletal trauma.(1) About 40% of all US
white women will suffer at least one clinically apparent fragility
fracture during their lifetime.(2) The consequences of fractures,
commonly occurring in the spinal vertebrae, wrists, and hip, pose
a serious health risk to the patients and have a profound social
and economic impact.(3)
High and low bone mineral densities (BMDs) are typically
associated with strong and fragile bones, respectively. Reduced
BMD leads to osteoporosis, deﬁned by the World Health Organi-
zation (WHO) as a BMD of 2.5 standard deviations (SDs) or more
below the young adult mean (T-score ≤ −2.5). BMD is highly her-
itable. Mothers with low BMD have children with signiﬁcantly
lower BMD more frequently than the general female popula-
tion.(4) Also, studies involving twins or kin relationships have
demonstrated that individual variations in BMD are up to 80%
genetically determined.(5–7) A recent genomewide association
study (GWAS),(8) the most extensive so far, identiﬁed 518 loci
accounting for approximately 20% of heel BMD variation. Some
of the discrepancies between that GWAS and family studies may
be explained by different epigenetics between osteoporotic and
healthy subjects, as indicated by recent DNA methylation stud-
ies and difﬁculties detecting disease associated genetic variants
due to minor contribution.(9–11) MicroRNAs (miRNAs) are consid-
ered part of the possible epigenetic mechanisms contributing to
osteoporosis risk, and their regulatory effect are heritable.(12,13)
miRNAs are 19-nucleotide (nt)-long to 24-nt-long noncoding
molecules that are distinct from, but related to, small interfering
RNAs (siRNAs), and have been identiﬁed in a variety of organ-
isms.(14) They are transcribed from distinct genes and regulate
the translation and/or degradation of speciﬁc messenger RNAs
(mRNAs) or other transcripts, thereby modulating many critical
cellular signaling pathways and functions.(14) The miRBase data-
base (release 22; Manchester University, Manchester, UK; http://
www.mirbase.org/) contains well over 2500 mature human
miRNAs.(15) Despite the critical importance of miRNAs in the
regulation of various cell functions, their role in osteoporosis
has not yet been investigated in depth in well-characterized
human bone.
In addition to miRNAs, thousands of other noncoding RNAs
(ncRNAs) are transcribed from the human genome, andmay reg-
ulate gene expression at transcription, RNA processing, and
translation levels.(16) These untranslated RNAs include small
nucleolar RNAs (snoRNAs, SNORDs, SNORAs), most of which are
pieces of introns (~70 nt) that have separate functions after
being excised through exonucleolytic processing.(17) The snoR-
NAs are essential for pre-ribosomal RNA (pre-rNA) processing,
catalyze nucleotide modiﬁcations, and may also serve to chaper-
one the correct RNA fold for rRNA processing and ribosome
assembly.(18)
We aimed to establish a putative association of ncRNAs with
BMD or fracture by performing global gene expression proﬁling
of bone biopsies from postmenopausal white women with bone
mass varying from healthy to osteoporotic with or without prior
fragility fractures. mRNA levels vary considerably between
weight-bearing (WB) spine and non–weight-bearing (NWB) iliac
bone in the same individuals.(19,20) To make the present study
representative for different skeletal sites, we included NWB iliac
and WB femoral bone where the most serious fractures occur.
Subjects and Methods
Ethics statement
The study was approved by the Norwegian Regional Ethical
Committee (REK no 2010/2539, Norway), all volunteers gave
their written informed consent, and sampling and procedures
were according to the Act of Biobanking in Norway.
Participants
The cohort of iliac bone donors was enlisted after completing a
questionnaire that included questions on lifestyle factors and
was deemed representative of the Oslo-based Norwegian ethnic
female population aged 50 to 86 years. Nonrelated postmeno-
pausal ethnic Norwegian women (50 to 86 years, n = 300) were
recruited from the outpatient clinic of Lovisenberg Diaconal Hos-
pital (Oslo, Norway). Of these, 177 were excluded from the study
due to medication or diseases other than primary osteoporosis
that are known to alter bone metabolism. Altogether,
100 women were enrolled in the study, and underwent transiliac
bone biopsies of the anterior superior iliac crest. Eighty-four
biopsies underwent gene expression analysis. The biochemical
and physiological parameters of these women have been
described.(11) Moreover, site-speciﬁc BMD was evaluated with
Lunar Prodigy DEXA (GE Lunar, Madison, WI, USA) following the
manufacturer’s instructions. The precision of the instrument for
measuring the lumbar spine (L2–L4) and hip BMD was 1.7% and
1.1%, respectively.
Femoral bone intertrochanteric biopsies were obtained from
postmenopausal women (n = 18) with a wide BMD range, ie,
from healthy to osteoporotic, who were undergoing hip replace-
ment surgery (Table 1). None of the participants had medication
or diseases other than primary osteoporosis known to affect
bonemetabolism. Anthropometric data, including BMD, for each
of the 18 donors are shown in Table S1.
Puriﬁcation and quantiﬁcation of ncRNAs
Total RNA was isolated from bone biopsies as described(11) and
quality checked using Agilent BioAnalyzer (Agilent Technologies,
Santa Clara, CA, USA).
For analysis of the iliac ncRNAs, total RNA (45 ng) was reverse-
transcribed using Megaplex TM reverse transcription
(RT) primersets A and B (Applied Biosystems, Foster City, CA,
USA). TaqMan miRNA LDA Arrays A and B (Applied Biosystems)
were used for proﬁling 758 different ncRNAs. The data were ana-
lyzed using SDS 2.3 software (Applied Biosystems, Foster City,
CA, USA) and the comparative threshold cycle (ΔΔCt) method.
We used a restrictedmean of expressedmiRNAs, and normalized
between two plates with the same sample and performed a nor-
malization across samples.
For mature miRNA and ncRNA microchip expression proﬁling
of femoral bone intertrochanteric RNA, 300 ng total RNA was
used for biotin labeling by a Genisphere FlashTag HSR kit
(Genisphere, Hatﬁeld, PA, USA) according to the manufacturer’s
protocol. Labeled miRNAs were hybridized to the GeneChip
miRNA 4.0 Array (Affymetrix, Santa Clara, CA, USA). Affymetrix
CEL ﬁles (containing probe intensities) were imported into Partek
Genomics Suite software (Partek, St. Louis, MO, USA). Robust
microarray analysis (RMA) was applied for normalization.
Lasso-selected femoral miRNAs from microarray data were
validated using RT-PCR with Fast Advanced reagents (Thermo
Fisher Scientiﬁc, Waltham, MA, USA), 384-well plates, and the
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QuantStudio 12 K Flex Real-Time PCR System (Thermo Fisher Sci-
entiﬁc, Waltham, MA, USA). miR-361-3p, miR-24-3p, and miR-107
were used as internal standards because microarray analysis
showed that their levels were similar in all samples.
The seven miRNAs in Table S5 resulted in measurable PCR prod-
ucts. The following assays were used (all from Thermo Fisher
Scientiﬁc): miR-29c-3p: 479229_mir; miR-1-3p: 477820_mir;
miR-1260b: 477886_mir; miR-484: 478308_mir; miR-3652:
480799_mir; miR-361-3p: 478055_mir; miR-24-3p: 477992_mir;
miR-107: 478254_mir; miR-3921: 479742_mir; miR-92a-1-5p:
479205_mir; and miR-489-3p: 478130_mir.
Correlation studies
The Benjamini and Hochberg procedure(21) was used for control-
ling the false discovery rate (FDR). The correlation coefﬁcient was
computed between variation in the expression levels of each
mature miRNA/ncRNA expressed in 95% of the biopsies and
the BMD for all subjects (n = 84). For each RNA, the null-
hypothesis of zero correlation was tested against the two-tailed
alternative hypothesis. Correlation coefﬁcients were computed
for BMD adjusted for age (Z-score) and BMI, ﬁrst by regressing
the BMD Z-score on BMI values (with intercept), and then deﬁn-
ing the residuals as the BMI-adjusted Z-scores.
Lasso analysis and cross-validation
In addition to identifying the individual transcripts showing sig-
niﬁcant correlation with BMD, we also selected a set of tran-
scripts that together accounted for a substantial percentage of
the BMD variation. The set was selected using the Lasso method
for variable selection and shrinkage in regression models.(22)
Cross-validation was performed to estimate the penalty parame-
ter of the Lasso method. The Lasso analysis, including the cross-
validation step, was performed for BMD Z-scores adjusted for
BMI in total hip, femoral neck, and spine (L2–L4) using the R-
package lars(22) (http://cran.r-project.org/web/packages/lars/
index.html)(23) and the R-package glmnet (https://cran.r-project.
org/web/packages/glmnet/index.html). The R2 value for each
estimated model was also computed. To compare the perfor-
mance of the selected sets of transcripts to a random selection
of transcripts, the R2 value of an ordinary least squares regression
with the selected set was compared to the R2 values of an ordi-
nary least squares regression for each of 10,000 randomly
selected sets of the same. The p value was calculated as the pro-
portion of the random sets with a higher R2 value than the Lasso-
selected set.
Gene enrichment analysis
We used mirPath v.3 in DIANA TOOLS (http://diana.imis.athena-
innovation.gr/DianaTools/index.php),(24) which has high sensi-
tivity and relatively high precision,(25) to identify overrepre-
sented pathways among the iliac and femoral bone miRNAs
correlated with adjusted total hip BMD at 10% FDR (Table 4).
Calculation of fracture associated iliac bone ncRNAs
To test whether the expressions of the transcripts were related to
fracture, a logistic regression model was ﬁtted for each of the
303 transcripts from iliac bone, with fracture (yes/no) as the
response variable and transcript, age, and BMI as explanatory
variables. TheWald test p values were corrected for multiple test-
ing by using the Benjamini and Hochberg procedure.(21) In this
analysis, 47 iliac bone donors without fracture and 36 with previ-
ous fracture were included. Out of the 36, 23 had at least one ver-
tebral fracture and 27 had at least one nonvertebral fracture
(wrist or femoral neck). Associations with fracture were per-
formed only for iliac bone donors because only two of the femo-
ral bone donors did not have fracture.
Cis-eQTL (expressed quantitative trait loci) analysis of iliac
bone samples
Genomewide genotyping of the iliac bone donors was per-
formed using the Affymetrix Axiom Biobank Genotyping Array
(Affymetrix, Santa Clara, CA, USA) (~700,000 SNPs assessed),(26)
followed by imputation to the haplotype reference panel (HRC
1.0). SNPs with minor allele frequency (MAF) > 0.05 and imputa-
tion quality (R2) > 0.3 were considered for further analysis. Com-
bining the available genotyped patient data and iliac bone
ncRNA expression data of patients yielded data of 77 patients
in total. We then used a two-step approach to assess the associ-
ation of SNPs with the expression of each ncRNA. First, using lin-
ear models we adjusted the ncRNA expression for either age or
age and BMI, and then deﬁned the model residuals as either
age-adjusted RNA expressions or age- and BMI-adjusted RNA
expression. These model residuals were scaled using zero mean
unit variance standardization. Second, we performed cis-eQTL
analyses, using the Rvtests software package with single variant
tests,(27) for each adjusted ncRNA expression. SNPs within
500 kilobases (kb) of the ncRNA transcription start or termina-
tion sites were surveyed. Values of p of association were
adjusted for multiple testing (FDR < 0.05).
Table 1. Demographic, Clinical, and Laboratory Parameters of
Femoral Bone Biopsy Donors
Parameter Average SD
Laboratory
reference
ranges
Age (years) 74.31  4.62 NA
BMI (kg/m2) 23.40  2.85 NA
Serum total-PTH (pmol/L) 4.43  1.89 1.10–7.70
Ionized Ca2+ (mmol/L) 1.20  0.03 1.15–1.35
Serum Ca2+ (corrected, mmol/L) 2.38  0.08 2.15–2.51
Serum-25(OH)vitD (nmol/L) 52  20 30–110
BGLAP (osteocalcin) (nmol/L) 2.41  1.41 <3.6
CTX-1 (μg/L) 0.53  0.18 <0.85
Serum bone speciﬁc alkaline
phosphatase (μg/L)
24.44  12.51 11.6–30.6
BMD, total femoral neck (g/cm2) 0.77  0.10 NA
BMD, total femoral neck (T-score) −1.87  0.87 NA
BMD, total femoral neck (Z-score) −0.18  0.83 NA
BMD, total femoral neck
(BMI-adjusted Z-score)
0.00  0.83 NA
BMD, total body (g/cm2) 1.05  0.10 NA
BMD, total body (T-score) −0.73  1.32 NA
BMD, total body (Z-score) 0.86  1.22 NA
BMD, total body (BMI-adjusted
Z-score)
0.00  1.21 NA
All biopsies were taken from the intertrochanteric region.
NA = not applicable; CTX-1 = carboxyterminal collagen crosslinks (bone
resorption marker); Z-score = age adjusted T-score.
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Veriﬁcation of expression of relevant miRNAs in
osteoblasts/osteocytes
About 95% of bone cells constitute osteoblasts/osteocytes, but
the bone biopsies also contained bone marrow, including non-
bone cell types. Thus, it was necessary to examine whether the
BMD associated miRNAs were expressed in osteoblasts/osteo-
cytes. For this purpose we took advantage of data from De-
Ugarte and colleagues,(28) who performed microarray proﬁling
of primary osteoblasts obtained frombone biopsies taken during
knee replacement due to osteoarthritis (n = 4, NCBI GEO reposi-
tory, accession number GSE74211).
Results
Cohorts and experimental strategy
We used bone biopsies from two cohorts of postmenopausal
women (age range, 50 to 86 years), and statistical analyses were
carried out as outlined in Fig. 1.
Demographic, clinical, and laboratory parameters of the
iliac bone donors
Demographic, clinical, and laboratory parameters of the iliac
bone donors, have been described.(11) Brieﬂy, the mean  SD
age and BMI of the 84 subjects were 64.6  9.6 years and 24.2
 3.6 kg/m2, respectively. They had a wide range of BMD of
the spine (L2–L4; T-score range: −6.2 to 2.9), femoral neck (−4.1
to 1.3), and total hip (−4.1 to 2.0), spanning osteoporotic to nor-
mal BMD. All participants had normal clinical, biochemical, and
nutritional status. The mean levels of parathyroid hormone
(PTH), vitamin K, Ca2+, phosphate, and 25(OH) vitamin D, as well
as the bone remodeling parameters osteocalcin, pyridinoline
cross-linked carboxyterminal telopeptide of type I collagen
(1CTP) and bone-speciﬁc alkaline phosphatase were all within
normal reference ranges.(11) Quantitative histomorphometry in
an additional seven women (T-score total hip range: −3.3 to
1.1) showed no change in osteocyte number between normal
and osteoporotic trabecular bone from iliac crest.(11)
Demographic, clinical and laboratory parameters of the
femoral bone donors
Data on the femoral bone donors are presented in Table 1. This
cohort consisted of postmenopausal women (n = 18) with a wide
range in BMD, from healthy to osteoporotic, undergoing hip
replacement surgery.
Identiﬁcation of BMD-associated ncRNAs in iliac or
femoral bone biopsies
Table 2 summarizes signiﬁcant correlations found between gene
expression signal strength of ncRNAs originating from either iliac
or femoral bone and BMD variation in the same donors. For iliac
bone, 303 ncRNAs were detected in >95% of the samples and
Fig. 1. Overview of cohorts, methods, and biostatistics with summary results.
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were used for all remaining statistical analyses. For femoral bone,
analyzed by microarrays, ncRNA transcripts with log2 signal <5
across all samples were omitted.
In iliac bone, when accounting for multiple testing, applying
FDRs of varying stringency (1%, 5%, 10%), 36, 58, and 75 tran-
scripts, respectively, correlated with BMI-adjusted total hip Z-
score (age adjusted T-score) (Table 2). Table 2 also shows the cor-
responding numbers for the femoral neck and L2–L4 BMI-
adjusted Z-scores. In femoral bone, no ncRNAs were identiﬁed
for total hip BMI-adjusted Z-score at 1% or 5% FDR, but 94 were
identiﬁed at 10% FDR. Table 2 shows that in femoral bone as well
as in iliac bone, more transcripts were correlated to BMD at the
total hip as compared to BMD at the femoral neck and the lum-
bar regions after adjustment for FDR. The correlated transcripts
identiﬁed for the different skeletal sites at ≤10% FDR are pre-
sented in Table S2 (iliac bone) and Table S3 (femoral bone).
The relative amounts of the 36 iliac ncRNAs at 1% FDR are pre-
sented in Fig. S1.
The Venn diagram in Fig. 2 shows that, out of 94 femoral bone
and 75 iliac bone ncRNAs associated with total hip BMD (FDR
≤10%), eight were common and represented miRNAs (Fig. S2).
Interestingly, ﬁve of the femoral miRNAs showed a positive cor-
relation to total hip BMD, whereas in iliac bone they were
inversely correlated (miR-27a-5p, miR-28-3p, miR-328-3p, miR-
409-3p, and miR-484), indicating an unexpected difference
between the two sites.
Lasso analysis
Lasso analysis is a regression-based analytical method com-
monly used when variables outnumber samples.(29,30) We used
Lasso analysis as a separate independent statistical method on
both cohorts of bone donors to identify sets among all detected
transcripts that would explain a high proportion of BMD. The
Lasso analysis selected nine ncRNAs in both iliac and femoral
bone. The degree of explained total hip BMD variation after
adjustment for age and BMI was calculated from an ordinary
least squares regression model with the selected ncRNAs, and
was 53% (R2 = 0.53, p = 1.0E–4) and 88% (R2 = 0.88, p = 3.0E–5)
for iliac bone and femoral bone, respectively (Table 3). Absence
of ncRNAs selected for femoral ncRNAs associated with total
femoral neck and spine is probably due to weaker associations
and few samples, because the number of selected variables
depends on sample size.
Because it is possible that the Lasso-selected sets of ncRNAs
could explain a large proportion of the variation in BMD just by
chance, we compared the results (R2 = 0.53 and R2 = 0.88) to
the R2 of the ordinary least squares regressions for 10,000 ran-
domly selected sets of ncRNAs with set sizes of nine. On average,
the random sets resulted in R2 = 0.26 and R2 = 0.74 for iliac bone
and femoral bone, respectively, which is clearly lower than what
was found as variance explained of total hip BMD for the initial
Table 2. Number of ncRNAs from Iliac or Femoral Bone Correlating With Total BMD at Different Sites
Parameter Unadjusted p < .05 FDR 1% FDR 5% FDR 10%
A. Number of BMD-associated ncRNAs from iliac bone
Total hip 90 36 58 75
Femoral neck 83 11 52 67
L2–L4 67 0 17 33
B. Number of BMD-associated ncRNAs from femoral bone
Total hip 186 0 0 94
Femoral neck 69 0 0 0
L2–L4 220 0 0 36
The table shows number of BMD correlated ncRNAs derived from iliac bone (A) and femoral bone (B) after correction for variation in age and BMI at
indicated sites with unadjusted p value and with different levels of FDR. BMI = body mass index.
Fig. 2. Common BMD-associated ncRNAs between iliac and femoral
bone adjusted for variation in age and BMI. The Venn diagram shows
numbers of common and site-speciﬁc ncRNAs in iliac and femoral bone
at 10% FDR. The eight common transcripts are presented in Fig. S2.
Table 3. Statistical Parameters for the Lasso Selected Sets of
ncRNAs in Iliac and Femoral Bone
Parameter Total hip
Total
femoral
neck
Spine
(L2–L4)
Results for iliac bone ncRNAs
R2 (number of ncRNAs) 0.53 (9) 0.44 (7) 0.87 (33)
p value 1.0E−04 1.0E−04 1.0E−04
Average R2 0.26 0.20 0.49
Results for femoral bone ncRNAs
R2 (number of ncRNAs) 0.88 (9)
p value 3.0E−02
Average R2 0.74
R2 values were calculated for ordinary least squares regression models
as described in Subjects and Methods. In parentheses, the number of
ncRNAs selected by the Lasso analysis and used for calculation of R2
values. As control, average R2 and p values were calculated from 10,000
random sets of the same size as those selected by Lasso for the respec-
tive anatomical sites. Lasso did not select femoral ncRNAs associated
with total femoral neck nor spine. This is probably due to weaker associ-
ations and because of few samples as the number of selected variables is
dependent on sample size.
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Lasso-selected sets. None of the random sets for iliac bone (total
hip, total femoral neck, L2–L4) had R
2 as large as the sets identi-
ﬁed by Lasso analysis.
Seven of the nine Lasso-identiﬁed iliac bone ncRNAs were
among the 36 that were signiﬁcantly correlated (<1% FDR) to
adjusted total hip BMD (Tables S2 and S4A). Furthermore, eight
of the nine Lasso-identiﬁed femoral ncRNAs were among the
set of 94 ncRNAs correlating (<10% FDR) to total hip BMD
adjusted Z-score (Tables S3 and S4B). Table S4A lists all of the
selected Lasso-identiﬁed iliac ncRNAs for age- and BMI-adjusted
BMD for total hip (n = 9), total femoral neck (n = 7), and L2–L4
(n = 33). Table S4B shows the corresponding Lasso-identiﬁed
femoral bone ncRNAs. Notably, Lasso identiﬁed no common
ncRNAs between iliac and femoral bone.
Femoral bone BMD-associated miRNAs were also veriﬁed by
PCR (Table S5), showing correlation r values in the same direction
as found in Lasso analysis, although with p values >.05, possibly
due to the limited number of samples. Although the nine femo-
ral ncRNAs identiﬁed by Lasso and microarray analysis could
explain 88% (R2 = 0.88) of the variation in adjusted total hip
BMD, PCR and multiple linear regression analyses of seven of
these femoral bone ncRNAs could explain 44% (R2 = 0.44) of
the variation in the adjusted total hip BMD, thus supporting
microarray and Lasso ﬁndings. Relative levels of the PCR tested
miRNAs are presented in Fig. S3.
Identiﬁcation of fracture associated ncRNAs
Using a logistic regression model (Subjects and Methods) we
identiﬁed 29 ncRNAs to be associated with any previous fracture
in the cohort of iliac bone donors at adjusted p < .05. The top-
most fracture associated ncRNAs (adjusted p < .1) are listed in
Table S6. Out of the 36 women with fracture 23 had at least
one vertebral compression fracture.
Of the 29 fracture-associated iliac miRNAs, only miR-16-1-3p
and miR-23a-3p were not among the ncRNAs correlated to
BMD in Table S2. To test whether they were associated with
hip bone geometry they were correlated to hip structure param-
eters in n = 80 of the same bone donors. Hip bone geometry in
these donors has been described.(31) Interestingly, miR-16-1-3p
showed nominally signiﬁcant correlation with neck shaft angle
(r = −0.22, p = .050) and section modulus of the femoral neck
(r = 0.22, p = .050).
The PCA plot (Fig. 3A) is based on all detected iliac ncRNAs,
and indicates that iliac bone donors with fracture has a common
ncRNA expression proﬁle that at least partly separates them from
donors without fracture. The woman representing the leftmost
blue outlier ball had nonvertebral as well as vertebral fractures,
thus suggesting an underlying disease, although all biochemical
markers were normal. The PCA plot in Fig. 3B is also based on all
iliac ncRNAs and shows grouping of donors with T-score ≤ −2.5
(blue balls) as compared to donors with normal BMD (T-
score > −1, red balls).
Functional annotation clustering of predicted miRNA
targets in iliac and femoral bone
Gene enrichment analysis showed that the majority of the iden-
tiﬁed pathways are speciﬁc to either iliac or femoral bone
(Table 4). As expected, extracellular matrix (ECM)-receptor inter-
action, being central in bone metabolism, was the second most
signiﬁcantly enriched pathway at both skeletal sites. Moreover,
fatty acid metabolism was more prominent in iliac bone than
in femoral bone.
Cis-eQTL analysis of iliac bone samples
DNA from the iliac bone biopsies has previously undergone gene
proﬁling using the Affymetrix UK Biobank Axiom Array.(26) To
evaluate whether SNPs within a 1-megabyte (MB) window of
the ncRNA-encoded regions inﬂuenced the ncRNAs levels, we
performed two cis-eQTL analyses, adjusting for age and for age
and BMI (Subjects and Methods). At q < 0.05, rs12187909 was
associated with miR-449b-5p (p = 4.14E–5) and rs74918612 asso-
ciated with miR-331-3 (p = 7.59E–4). The former came out as sug-
gestively correlated when adjusting ncRNA expressions only for
age, and the latter when adjusting ncRNA expressions for age
and BMI (Table 5). Tables S7 to S11 include detailed results from
the cis-eQTL analysis, including all ncRNA-associated SNPs
adjusted for age or age and BMI with q values. These tables also
present p values for the same SNPs from the GWAS byMorris and
colleagues(8) on estimated heel bone mineral density (eBMD).
Figures S4 and S5 show the squared coefﬁcients of correlation
(R2) between different SNPs, as curated from the cis-eQTL analy-
sis results with age as predictor, where their respective q values
were both <0.1 for miR-449b-5p and miR-331-3p.
Fig. 3. PCA of iliac bone donors. (A) Distribution of all iliac bone donors with any fracture (blue balls) versus those without (red balls). (B) Distribution of
osteoporotic iliac bone donors (T-score ≤ −2.5) versus controls (T-score > −1). PCA = principal component analysis.
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Discussion
We present the hitherto most comprehensive study characteriz-
ing functional ncRNA expression patterns in NWB iliac and WB
femoral bone in well-characterized cohorts of osteoporotic and
healthy postmenopausal white women. Comparisons between
the BMD-correlated ncRNAs expressed at the two sites revealed
major differences with minor overlap and distinct, overrepre-
sented signaling pathways. Lasso analysis of the bone ncRNAs
enabled the identiﬁcation of small sets of ncRNAs explaining a
signiﬁcant proportion of BMD variation measured at different
skeletal site. We also identiﬁed miRNAs associated with fracture
or SNPs.
The common pathways affected by BMD-associated miRNAs
in both iliac and femoral bone include that for ECM-receptor
interaction and proteoglycans in cancer, both of which are obvi-
ously important in all types of bone. The three other common
pathways, Amoebiasis, Glioma, and Lysine degradation, have
no obvious function in bone and may be the result of miRNA tar-
gets being common to several functional pathways. For exam-
ple, the glioma pathway includes miRNA targets such as
mammalian target of rapamycin (MTOR), platelet-derived growth
factor receptor alpha (PDGFRA), and epidermal growth factor
(EGF), which have established functions in bone
metabolism.(32–34) The ECM–receptor interaction pathway
involves interactions between various cell-associated integrins
Table 4.Overrepresented Biochemical and Cellular Signaling Pathways Predicted to be Affected by BMD Associated miRNAs in Iliac and
Femoral Bone
KEGG pathway p Genes (n) miRNAs (n)
Iliac bone
Fatty acid biosynthesis1 <1E−325 5 4
ECM-receptor interaction2 <1E−325 47 12
Mucin type O-Glycan biosynthesis1 <1E−325 19 16
Amebiasis2 8.86E−10 21 4
Fatty acid metabolism1 2.44E−08 16 7
Glioma2 9.50E−08 44 13
Proteoglycans in cancer2 2.27E−05 106 13
Signaling pathways regulating pluripotency of stem cells1 8.13E−05 71 8
Glycosaminoglycan biosynthesis – heparan sulfate/heparin1 2.42E−04 9 10
Focal adhesion1 6.62E−03 100 7
Lysine degradation2 1.05E−02 18 9
PI3K-Akt signaling pathway1 1.32E−02 131 7
Amphetamine addiction1 1.81E−02 32 13
Femoral bone
Prion diseases3 <1E−325 1 2
ECM-receptor interaction2 <1E−325 31 7
Metabolism of xenobiotics by cytochrome P4503 1.46E−06 14 9
Proteoglycans in cancer2 1.85E−04 101 12
Lysine degradation2 2.15E−03 17 10
Hippo signaling pathway3 4.21E−03 71 11
Glycosphingolipid biosynthesis – lacto and neolacto series3 5.48E−03 10 8
Morphine addiction3 1.20E−02 31 7
Amebiasis2 1.63E−02 20 2
Thyroid hormone synthesis3 1.86E−02 9 6
Glioma2 3.52E−02 33 8
The table shows predicted affected KEGG pathways at p values <.05 using DIANA – mirPath v.3 with the following settings: pathways intersection, FDR
correction (conservative stats: left unchecked).
1 Pathways speciﬁc to iliac bone.
2 Pathways common to iliac and femoral bone.
3 Pathways speciﬁc to femoral bone.
Table 5. Cis-eQTL Analysis on Levels of Iliac Bone ncRNAs
Locus area (containing SNPs associated with indicated
miRNAs at q value <0.05)
miRNA Chromosome POS start POS end Covariate
Locus previously
associated
with BMD(8)
Correlation
with total
hip T-score (r)
miR-331-3p 12 95364009 96149571 Age and BMI Yes(8) −0.58
miR-449b-5p 5 54651510 54896300 Age No −0.35
Details of the Cis-eQTL analysis are found in the Supplemental Data. POS = Position.
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and matrix collagens which are central actors in bone metabo-
lism. This pathway overlaps with the focal adhesion pathway,
ranked tenth in iliac bone but ranked as not signiﬁcant in femoral
bone. Notably, the focal adhesion pathway is linked to the Wnt
pathway, which is central to bone metabolism.(35) Other iliac
bone pathways related to bone matrix include that for mucin
O-glycan biosynthesis and glycosaminoglycan biosynthesis,
which are of obvious relevance to BMD.
The pathways speciﬁc to iliac bone also include that for fatty
acid biosynthesis and fatty acid metabolism. It is well known that
bone marrow stem cells (BMSCs) tend to differentiate toward
adipocytes rather than osteoblasts in osteoporotic bone,(36)
and an inverse association between BMD and marrow adipose
tissue has been demonstrated in different populations.(37) A
larger study with higher power might be able to detect these
pathways in WB femoral bone.
It is unclear how several of the identiﬁed pathways targeted
speciﬁcally by femoral bone miRNAs are associated with BMD,
with the exception of the Hippo signaling pathway. The Hippo
signaling pathway is important for stem cell function, bone
development, and bone remodeling via interactions with, eg,
the transforming growth factor beta (TGF-β)/SMAD pathway,
Wnt signaling, and the transcription factor RUNX2 (RUNX family
transcription factor 2).(38) Supporting the relevance of these ﬁnd-
ings in bone tissue, 22 of 46 ncRNAs have been shown to be
important for bone cell differentiation and function in cell and
animal models (Table S5).
Figure S2 shows that some ncRNAs were positively correlated
to BMD when expressed in WB bone, but inversely when
expressed in NWB bone. Transcript levels have previously been
shown to vary widely between WB and NWB bone. For example,
the transcription factor ZIC1 was shown to be expressed 200-fold
higher in male bone biopsies from WB lumbar spine as com-
pared to NWB iliac crest in the same donors.(20) In the same
study, more than 4000 genes were identiﬁed as differentially
expressed between the two sites. Thus, the observed inverse
associations may reﬂect another aspect of differential bone
metabolism in WB and NWB bone.
We searched the literature to identify whether the total hip
BMD associated ncRNAs from iliac bone and femoral bone have
been experimentally shown to impact bonemetabolism. The rel-
evant studies are summarized in Table S12. Brieﬂy, 22 of the
46 ncRNAs have been associated with bone metabolism and/or
osteogenic cell differentiation; eg, miR-92a-1-5p inﬂuences oste-
ogenic differentiation in vitro by regulating β-catenin(39) and
reduces body and skull length in miR-92a−/−mice(40) and inhibi-
tion of miR-92a-1-5p enhances fracture healing.(41) The miR-15a-
5p is part of the deleted in lymphocytic leukemia 2 (DLEU2) gene,
which is highly correlated to BMD in postmenopausal women(11)
and mice (own results unpublished). In addition, miR-149-5p
may be of clinical importance, because polymorphisms within
its encoded primary RNA sequence have been associated with
vertebral fractures in postmenopausal Korean women.(42) Most
of the miRNAs in Table S7 affect functions attributed to bone cell
differentiation and mineralization involving both osteoblast and
osteoclast lineages conﬁrming their skeletal functionality.
The bone biopsies contain also non-bone cells, and it may be
argued that some of the BMD-associated ncRNAs are not origi-
nating from bone cells. However, all but ﬁve of the 36 topmost
femoral bone miRNAs signiﬁcant at 10% FDR (Table S3) when
correlated to BMI=adjusted total hip Z-score were also produced
in cultured differentiated normal human osteoblasts (publicly
available data described by De-Ugarte and colleagues(28); not
shown). Notably, the ﬁve miRNAs not found were not covered
by the GPL20999 miRCURY LNA miRNA Array used to proﬁle
the osteoblast miRNAs.
Notably, separate sets of small nucleolar RNAs (SNORAS,
SNORDS, or snRNAs) from iliac and femoral bone were correlated
with BMD. In iliac bone, SNORD44 and SNORD48, which direct
20O-ribose methylation of 18S rRNA and 28S rRNA,
respectively,(43–45) were negatively correlated with BMD, whereas
28SrRNA was positively correlated with BMD (Table S2). Interest-
ingly, 28SrRNA showed an inverse correlation with SNORD44 and
SNORD48 (r = −0.57 and r = −0.81; p = 1.2E−8 and p = 1.0E−15,
respectively). rRNA methylation is important for rRNA processing
and function, and failure in rRNA methylation has been linked to
several diseases.(46) The connection between BMD and rRNA levels
is supported by the identiﬁcation of functional RUNX2 binding
sites within DNA repeats encoding rRNA(47) and the fact that
RUNX2 suppresses rRNA gene transcription during osteoblast line-
age progression.(48,49) In iliac bone, 28S rRNA was signiﬁcantly cor-
related to nearly all BMD-correlated miRNAs at 1% FDR (not
shown). This may be due to the expansion segments of 28S rRNA,
which have been suggested to constitute an important compo-
nent of miRNA balance by binding and decreasing (“sponging”)
the availability of GC-rich miRNAs and thereby aid the conserva-
tion of GC-rich mRNAs.(50) Iliac RNU11 (RNA, U11 small nuclear)
was positively correlated to BMD and has functions such as 50
splice site recognition at constitutive splicing, activation of
U2-dependent alternative splicing, and regulating the
U12-dependent spliceosome,(51) indicating that altered splicing
may be an important mechanism affected in osteoporosis.
In femoral bone at 10% FDR, another set of total hip BMD-
correlated nucleolar RNAs was found, consisting of seven
SNORDS catalyzing 20-O-ribose methylation of rRNA and ﬁve
SNORAS guiding rRNA pseudourididylation(52) (Table S3). The
majority of snoRNAs are encoded in the introns of host
genes,(53) and their expression levels are thus correlated with
their host gene transcripts and regulated similarly. Furthermore,
crosslinking studies have indicated that SNORDS/SNORAS can
also modify mRNAs,(54) thereby possibly affecting the level of
bone cell transcripts related to skeletal metabolism.
However, it is striking that several miRNAs that promote oste-
ogenesis/osteoblastogenesis in in vitro experiments are
inversely correlated to BMD. This, may seem counterintuitive at
ﬁrst and apply, eg, to the following iliac bone miRNAs: miR-
22-3p,(55–57) miR-31-5p,(58) miR-124-3p,(59–62) miR-34a-5p,(63)
miR-378a-3p,(64–66) miR-27a-5p,(67–71) miR-342-3p,(72,73) miR-
15b-5p,(74,75) and miR-10a(76); the femoral bone miRNAs: miR-
23b-3p,(77) and miR-181a-2-3p(78–80); as well as miR-48a-3p from
both femoral and iliac bone.(58) We suggest that changes in these
miRNAs compensate for further bone loss. Previously we showed
that SOST (sclerostin) gene transcription and serum sclerostin
levels were positively correlated to BMD and were reduced in
postmenopausal osteoporosis.(81) These changes could be attrib-
uted to hypermethylation of the SOST promoter in the same
cohort of iliac bone patients, a possible epigenetic regulation
aiming to balance the well-known sclerostin inhibition of osteo-
blast bone formation.(10)
It should be noted that several of the miRNAs with a positive
correlation with BMD also promote osteogenesis in vitro; eg, iliac
bone miRNAs: miR-29a-3p,(59,82–86) miR-28-5p,(87) miR-181a-
5p,(78–80) and miR-27a-5p(67–71); femoral bone miRNAs: miR-
335-5p,(88) miR-194-5p,(89) and miR-378a-5p,(64–66) as well as
miR-29c-3p (in femoral and iliac bone).(90) It is noticeable and
of potential importance that most of the osteogenesis-
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associated miRNAs inversely correlated to BMD are found in iliac
bone, whereas most of the osteogenic miRNAs positively corre-
lated to BMD, are detected in femoral bone.
Of the 29 fracture-associated ncRNAs (Table S6), it is striking
that all but one (miR-181a-5p) increase risk of fracture at
increased expression levels. Furthermore, miR-16-1-3p (adj.
p = .0356) and miR-23a-3p (adj. p = .0745) were not among any
of the ncRNAs correlated to BMD in Table S2, and may therefore
be particularly associated with structure, as also indicated by the
association of miR-16-1-3p with hip structure.
Because of the limited availability of human bone biopsies,
only a few similar, smaller ncRNA proﬁling studies have been per-
formed, and none has been performed on NWB iliac bone. In a
smaller study De-Ugarte and colleagues(28) determined that
miR-320a and miR-483-5p are increased in osteoporotic bone.
miR-320a was replicated in the present study, whereas miR-
483-5pwas detected but did not reach signiﬁcance. Amore com-
prehensive study by Seeliger and colleagues(91) indicated that
miR-21, miR-23a, miR-24, miR-25, miR-100, and miR-125b are
upregulated in osteoporosis using unadjusted statistics. They
were also detected in the femoral bone biopsies in the present
study, but did not reach signiﬁcance when correlated to BMD
adjusted for variation in age and BMI. Garmilla-Ezquerra and col-
leagues(92) compared expression of 760 miRNAs in explanted
osteoblasts from the femoral heads from patients with osteopo-
rotic hip fractures and used patients with osteoarthritis as surro-
gate controls. They found that miR-187 was increased in the
controls, whereas miR-518f was increased in the osteoporosis
group. Neither were identiﬁed in our femoral bone biopsies
using multivariate analyses.
It is tempting to speculate that mechanically sensitive miRNAs
would be associated with BMD and/or fracture, especially in WB
femoral bone, but very few of those identiﬁed in cell culture stud-
ies were associated with BMD or fracture in the current study. A
recent study(93) identiﬁed 10 miRNAs that changed expression
when mouse MLOY4 osteocytes were subjected to mechanical
strain. However, only two of the identiﬁedmiRNAs were identiﬁed
as BMD associated in our study. Of those, miR-29b-3p correlated
positively to BMI- and age-adjusted total hip BMDwhen expressed
in both femoral and iliac bone (Fig. S2) but showed reduced
expression in MLOY4 cells subjected to mechanical stress. In the
same study(93) miR-574-3p showed increased expression at
mechanical stress, but this miRNA was inversely correlated to
BMD when expressed in iliac bone (Table S2). Thus, it is hard to
conclude on the association between mechanically sensitive miR-
NAs and their levels in WB and NWB bone.
Cis-eQTL analyses of iliac bone identiﬁed two loci/miRNAs of
interest. The locus near the miR-331-3p coding sequence was
also identiﬁed in the hitherto most comprehensive GWAS on
heel eBMD.(8) However, none of the SNPs identiﬁed in the pre-
sent study were associated with eBMD in the GWAS by Morris
and colleagues,(8) nor were they in LD with any of the eBMD-
associated variants.
Morris and colleagues(8) did not attempt to explain the effect of
genomic variation on miRNA expressions but our ﬁndings may
offer an explanation. Given the biological background of miRNA
mechanism of action, an argument can be given for such a nondir-
ect association of miRNA with eBMD variants genomewide based
on the present results. Polymorphisms inﬂuencing miRNA varia-
tion are not inﬂuencing BMD variation directly due to epigenetic
regulation. It would be desirable to perform a replicate study with
a larger cohort, but acquisition of additional biological samples
from well-characterized participants will be difﬁcult to obtain.
Most of the BMD-correlated ncRNAs in iliac bone, and in fem-
oral bone, represent novel bone biology. The use of nontradi-
tional statistical methods, such as Lasso, allowed us to select
ncRNA sets maximizing the BMD variance explained. The power
of this technique was further conﬁrmed by a permutation analy-
sis. This and our previous study(11) conﬁne the large number of
transcripts expressed in bone biopsies (summing thousands) to
a nadir of nine ncRNAs identiﬁed through the Lasso analysis
and a limited set of mRNAs, which statistically are strongly asso-
ciated with BMD. These molecular components in bone, as pre-
sented in Tables 3 and S4, admittedly at the risk of
oversimpliﬁcation, present an initial schematic outline of an
emerging picture of ncRNAs having important roles for normal
bone remodeling in NWB iliac bone and WB femoral bone.
Our study has some limitations. The number of participants is
limited and the study includes only postmenopausal women of
Northwestern European background. Especially for femoral data,
power is a limiting factor in terms of the detected number of
BMD associated ncRNAs. With a larger cohort, power would be
stronger and more BMD associated ncRNA would probably be
detected. Nevertheless, our rigorous statistical analyses ensures
validity of our ﬁndings. The bone biopsies contain marrow,
hence the results may be somewhat inﬂuenced by transcripts
in this tissue. RNA sequencing of the samples indicated that mar-
row cells of hematopoietic and immunological lineage consti-
tuted a minor part (about 20%) of the total cell population
contained (not shown). Furthermore, it is expected that marrow
constituents across iliac and femoral bone biopsies would be
similar. Thus, the detected differences in ncRNA expression
between these two sites are most likely attributable to differ-
ences in bone cell expression levels. Twenty-two of 46 ncRNAs
have been ascribed functional bone cell signiﬁcance in different
experimental systems. Also, the most signiﬁcantly BMD-
correlated miRNAs have been found to be expressed in primary
cultured human osteoblasts. We used different platforms for pro-
ﬁling the iliac and femoral bone ncRNAs, but all ncRNAs proﬁled
in iliac bone were covered by microarrays used to proﬁle femoral
bone ncRNAs, thus supporting the validity of our ﬁndings. Still,
we acknowledge that detection methodologies (microarrays
with detection of biotin labeled ncRNAs versus TaqMan assays
involving detection of PCR products after cleavage of quenching
hybridizing probes) and quantiﬁcation analyses (eg, different
types of sample normalization, software, and thresholds) could
have an inﬂuence on the results. However, several papers show
that in general there is a very good concurrence in studies where
miRNA levels was measured by both GeneChip miRNA 4.0 Array
and TaqMan PCR analysis.(94–96)
The results invite to a more focused bone transcriptome and
functional analyses and thus represent a promising foundation
for pursuing studies of miRNAs and other ncRNAs preparing
the ground for future gene therapy of a common and devastat-
ing disease.
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